New Delhi, Aug. 10 -- Gland Pharma reported its June-quarter performance today, Monday, after market hours, with consolidated net profit rising 47% YoY to Rs.317 crore, compared with Rs.215.5 crore in Q1 FY26. However, on a sequential basis, net profit declined 14% from Rs.366.7 crore in Q4 FY26.

Revenue from operations increased 20% YoY to Rs.1,800 crore, from Rs.1,505 crore in the year-ago quarter and was up 3% sequentially from Rs.1,743 crore.

Business-wise, the CDMO business remained a key growth driver, with revenue rising 20% YoY to Rs.891.5 crore, while also registering an 11% sequential increase from Rs.805.9 crore, supported by recent product launches.

The B2B business revenue grew 19% YoY to Rs.908.8 crore, although it declin...